1 |
Faryabi J, Joolhar M. Treatments' outcomes of patients suffered from trigeminal neuralgia in kerman, iran. J Dent 2014; 15: 140-6.
|
2 |
Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991; 10: 276-81.
DOI
|
3 |
Childs AM, Meaney JF, Ferrie CD, Holland PC. Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports. Arch Dis Child 2000; 82: 311-5.
DOI
|
4 |
Mcquay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-52.
DOI
|
5 |
Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebocontrolled clinical trials. Clin Ther 2003; 25: 81-104.
DOI
|
6 |
Guo J, Dong X, Zhao X. Treatment of trigeminal neuralgia by radiofrequency of the Gasserian ganglion. Rev Neurosci 2016; 27: 739-43.
DOI
|
7 |
Hayes WJ, Ferdinand A, Neabore S, Kappes JA, Hayes KM, Berendse J. Patient case report: gabapentin-induced hypoglycemia. J Pharm Pract 2020; 1-4.
|
8 |
Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol 2020; 19: 784-96.
DOI
|
9 |
Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71: 1183-90.
DOI
|
10 |
Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-6.
DOI
|
11 |
Lee JE, Min KR, Kim SH, Kim AH, Kim ST. Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital. Yonsei Med J 2020; 61: 875-9.
DOI
|
12 |
Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002; 57: 451-62.
DOI
|
13 |
Cheshire WP Jr. Defining the role for gabapentin in the treatment of trigeminal neuralgia: a retrospective study. J Pain 2002; 3: 137-42.
DOI
|
14 |
Brid T, Sacristán De Lama MP, González N, Baamonde A. Topical gabapentin as add-on therapy for trigeminal neuralgia. a case report. Pain Med 2017; 18: 1824-6.
DOI
|
15 |
Agarwal N, Singh S, Kriplani A, Bhatla N, Singh N. Safety and efficacy of gabapentin in management of psychosomatic and sexual symptoms in postmenopausal women: a pilot study. J Midlife Health 2015; 6: 10-5.
|
16 |
Wei Y, Pu C, Li N, Ning L, Cai Y, Shang H, et al. Long-term therapeutic effect of microvascular decompression for trigeminal neuralgia: Kaplan-meier analysis in a consecutive series of 425 patients. Turk Neurosurg 2018; 28: 88-93.
|
17 |
Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. BJGP Open 2020; bjgpopen20X101120.
|
18 |
Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28: 491-6.
DOI
|
19 |
Holste K, Chan AY, Rolston JD, Englot DJ. Pain outcomes following microvascular decompression for drug-resistant trigeminal neuralgia: a systematic review and meta-analysis. Neurosurgery 2020; 86: 182-90.
DOI
|
20 |
Chang B, Zhu W, Li S. Effects of depression and anxiety on microvascular decompression outcome for trigeminal neuralgia patients. World Neurosurg 2019; 128: e556-61.
DOI
|